skip to main content
Idioma:

0457 COMORBIDITIES AND HEALTH-RELATED QUALITY OF LIFE AMONG PEOPLE WITH SLEEP APNEA WITH EXCESSIVE SLEEPINESS: FINDINGS FROM THE 2016 US NATIONAL HEALTH AND WELLNESS SURVEY

Stepnowsky, C ; Sarmiento, K ; Bujanover, S ; Villa, K ; Li, V ; Flores, N

Sleep (New York, N.Y.), 2017-04, Vol.40 (suppl_1), p.A170-A170 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
  • Título:
    0457 COMORBIDITIES AND HEALTH-RELATED QUALITY OF LIFE AMONG PEOPLE WITH SLEEP APNEA WITH EXCESSIVE SLEEPINESS: FINDINGS FROM THE 2016 US NATIONAL HEALTH AND WELLNESS SURVEY
  • Autor: Stepnowsky, C ; Sarmiento, K ; Bujanover, S ; Villa, K ; Li, V ; Flores, N
  • Assuntos: Comorbidity ; Generalized linear models ; Population-based studies ; Quality of life ; Sleep apnea
  • É parte de: Sleep (New York, N.Y.), 2017-04, Vol.40 (suppl_1), p.A170-A170
  • Descrição: Abstract Introduction: Few population-based studies have explored how excessive sleepiness (ES) contributes to burden of illness among patients with sleep apnea (SA). Methods: Data were obtained from the 2016 US National Health and Wellness Survey, an annual, representative, cross-sectional, general health survey (N=97,503). Respondents self-reporting a SA diagnosis were categorized as having ES (Epworth Sleepiness Scale [ESS≥11]) or not having ES (ESS<11) and compared with a non-SA control group. Respondents reporting narcolepsy were excluded. Measures included comorbidities and health-related quality of life (HRQoL; using SF-36v2) via the mental component summary (MCS), physical component summary (PCS) and health utility scores (SF-6D). Outcomes were examined by three groups: SA w/ES, SA w/oES, and non-SA controls using one-way ANOVAs (continuous outcomes) and chi-squares (categorical outcomes). Generalized linear models controlling for covariates examined the effect of SA/ES status on HRQoL. Results: Overall, SA w/ES was associated with higher comorbidities and lower HRQoL. The SA w/ES group (N=731) had a significantly higher proportion reporting depression (62.4% vs. 48.0%), unstable angina (6.4% vs. 4.1%), asthma (26.3% vs. 20.7%) and GERD (39.0% vs. 29.4%) compared to the SA w/oES group (N=1,452; all P<.05) and also compared to non-SA controls (N=86,961; P<.05). The SA w/ES group also had significantly lower HRQoL compared with the SA w/oES group and non-SA controls on MCS, PCS, and SF-6D (P<.05). After controlling for covariates, the burden of ES remained consistent as the SA w/ES group had significantly lower MCS (41.81 vs. 45.65 vs. 47.81), PCS (46.62 vs. 48.68 vs. 51.36), and SF-6D (0.65 vs. 0.69 vs.0.73) (all P<.001) compared with SA w/oES and non-SA controls. Conclusion: These data provide support that ES is associated with a substantial increased burden to SA patients as demonstrated by increased comorbidities and reduced HRQoL compared to those without ES and non-SA controls. Support (If Any): This research was funded by Jazz Pharmaceuticals.
  • Editor: US: Oxford University Press
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.